← Leaderboards
William George Nelson
Johns Hopkins University
$34,555,726
Attributed
$35,915,160
Total exposure
22
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11.8M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$175,356,035 · 25
By mechanism
P30$126,762,429 · 11
P50$35,808,653 · 8
T32$4,992,667 · 1
R01$4,738,300 · 2
U54$2,963,201 · 1
R03$79,785 · 1
Top collaborators
- Ben H Park7 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Paul Talalay$3,109,089
- Richard F. Ambinder$9,273,650
- Rena Xian$3,698,061
- Thomas W Kensler$20,869,769
- Theresa A Shapiro$12,921,052
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsOncologyComprehensive Cancer CenterMalignant NeoplasmsCancer Center Support GrantResource SharingFundingResearch PersonnelAnticancer ResearchClinical ResearchClinical TrialsTranslational ResearchInnovationMolecularPreventionDetectionDiagnosisUniversitiesCommunitiesMalignant Neoplasm Of ProstateScientistInsightCancer PreventionCancer Cell
Grant awards (197)
Regional Oncology Research Center$7,776,239
P30 · FY2025 · CA · contact PI
Developmental Funds$299,086
P30 · FY2025 · CA · contact PI
Leadership, Planning and Evaluation$299,086
P30 · FY2025 · CA · contact PI
Regional Oncology Research Center$145,988
P30 · FY2025 · CA · contact PI
Regional Oncology Research Center$103,977
P30 · FY2025 · CA · contact PI
Regional Oncology Research Center - Assessing Capacity to Address Obesity for CPC$100,000
P30 · FY2025 · CA · contact PI
Regional Oncology Research Center (Risk Factors)$100,000
P30 · FY2025 · CA · contact PI
Regional Oncology Research Center (Early Career Cancer Clinical Investigator Award)$65,105
P30 · FY2025 · CA · contact PI
Regional Oncology Research Center$7,776,239
P30 · FY2024 · CA · contact PI
Leadership, Planning and Evaluation$526,060
P30 · FY2024 · CA · contact PI
Developmental Funds$475,825
P30 · FY2024 · CA · contact PI
Regional Oncology Research Center (Stimulate Research in HIV/AIDS Supplement)$207,357
P30 · FY2024 · CA · contact PI
Regional Oncology Research Center (Heterogeneity)$100,000
P30 · FY2024 · CA · contact PI
Regional Oncology Research Center$7,776,239
P30 · FY2023 · CA · contact PI
Leadership, Planning and Evaluation$526,060
P30 · FY2023 · CA · contact PI
Regional Oncology Research Center (American Eurasian Cancer Alliance Supplement)$480,981
P30 · FY2023 · CA · contact PI
Developmental Funds$475,825
P30 · FY2023 · CA · contact PI
Regional Oncology Research Center (LLMs for Unstructured Data Extraction)$300,000
P30 · FY2023 · CA · contact PI
Regional Oncology Research Center (Social Determinants of Health Supplement)$249,785
P30 · FY2023 · CA · contact PI
Regional Oncology Research Center$100,000
P30 · FY2023 · CA · contact PI
Regional Oncology Research Center (Digital Tools and Interventions)$100,000
P30 · FY2023 · CA · contact PI
Regional Oncology Research Center$7,776,239
P30 · FY2022 · CA · contact PI
Leadership, Planning and Evaluation$526,060
P30 · FY2022 · CA · contact PI
Developmental Funds$475,825
P30 · FY2022 · CA · contact PI
Regional Oncology Research Center$51,029
P30 · FY2022 · CA · contact PI
Regional Oncology Research Center$50,309
P30 · FY2022 · CA · contact PI
Regional Oncology Research Center$7,070,833
P30 · FY2021 · CA · contact PI
Administrative Core$1,157,469
P30 · FY2021 · CA · contact PI
Developmental Funds$669,007
P30 · FY2021 · CA · contact PI
Regional Oncology Research Center$250,000
P30 · FY2021 · CA · contact PI
Regional Oncology Research Center$250,000
P30 · FY2021 · CA · contact PI
Regional Oncology Research Center$150,000
P30 · FY2021 · CA · contact PI
Planning and Evaluation$36,947
P30 · FY2021 · CA · contact PI
Regional Oncology Research Center$7,070,833
P30 · FY2020 · CA · contact PI
Administrative Core$1,157,469
P30 · FY2020 · CA · contact PI
Developmental Funds$669,007
P30 · FY2020 · CA · contact PI
Discovery and Pre-Clinical Translation of Rational Epigenetic-Drug/Targeted-Drug Targeted-Drug Combinations$212,224
P50 · FY2020 · CA · contact PI
Developmental Research Program$212,220
P50 · FY2020 · CA · contact PI
Career Development Program$212,220
P50 · FY2020 · CA · contact PI
Regional Oncology Research Center$199,691
P30 · FY2020 · CA · contact PI
Regional Oncology Research Center$199,687
P30 · FY2020 · CA · contact PI
Regional Oncology Research Center$198,971
P30 · FY2020 · CA · contact PI
Regional Oncology Research Center$148,434
P30 · FY2020 · CA · contact PI
Administrative Core$105,491
P50 · FY2020 · CA · contact PI
Planning and Evaluation$36,947
P30 · FY2020 · CA · contact PI
Regional Oncology Research Center$7,070,833
P30 · FY2019 · CA · contact PI
Administrative Core$1,157,469
P30 · FY2019 · CA · contact PI
Developmental Funds$669,007
P30 · FY2019 · CA · contact PI
Regional Oncology Research Center$200,003
P30 · FY2019 · CA · contact PI
Regional Oncology Research Center$60,000
P30 · FY2019 · CA · contact PI
Planning and Evaluation$36,947
P30 · FY2019 · CA · contact PI
Regional Oncology Research Center$7,069,034
P30 · FY2018 · CA · contact PI
Administrative Core$1,157,174
P30 · FY2018 · CA · contact PI
Developmental Funds$668,837
P30 · FY2018 · CA · contact PI
Discovery and Pre-Clinical Translation of Rational Epigenetic-Drug/Targeted-Drug Targeted-Drug Combinations$239,527
P50 · FY2018 · CA · contact PI
Regional Oncology Research Center$199,060
P30 · FY2018 · CA · contact PI
Developmental Research Program$152,201
P50 · FY2018 · CA · contact PI
Career Development Program$152,201
P50 · FY2018 · CA · contact PI
Administrative Core$134,657
P50 · FY2018 · CA · contact PI
Regional Oncology Research Center$59,984
P30 · FY2018 · CA · contact PI
Planning and Evaluation$36,938
P30 · FY2018 · CA · contact PI
Developmental Funds$6,865
P30 · FY2018 · CA · contact PI
Planning and Evaluation$6,865
P30 · FY2018 · CA · contact PI
Administrative Core$6,865
P30 · FY2018 · CA · contact PI
Administrative Core$2,069
P30 · FY2018 · CA · contact PI
Developmental Funds$2,069
P30 · FY2018 · CA · contact PI
Planning and Evaluation$2,069
P30 · FY2018 · CA · contact PI
Regional Oncology Research Center$7,060,038
P30 · FY2017 · CA · contact PI
Administrative Core$1,155,701
P30 · FY2017 · CA · contact PI
Developmental Funds$667,986
P30 · FY2017 · CA · contact PI
Discovery and Pre-Clinical Translation of Rational Epigenetic-Drug/Targeted-Drug Targeted-Drug Combinations$249,124
P50 · FY2017 · CA · contact PI
Career Development Program$162,138
P50 · FY2017 · CA · contact PI
Developmental Research Program$162,138
P50 · FY2017 · CA · contact PI
Administrative Core$148,303
P50 · FY2017 · CA · contact PI
Regional Oncology Research Center$125,000
P30 · FY2017 · CA · contact PI
Regional Oncology Research Center$60,000
P30 · FY2017 · CA · contact PI
Regional Oncology Research Center$59,007
P30 · FY2017 · CA · contact PI
Planning and Evaluation$36,891
P30 · FY2017 · CA · contact PI
Regional Oncology Research Center$6,995,267
P30 · FY2016 · CA · contact PI
SPORE in Prostate Cancer$1,827,641
P50 · FY2016 · CA · contact PI
DEVELOPMENTAL FUNDS$457,239
P30 · FY2016 · CA · contact PI
PROGRAM LEADERSHIP$449,436
P30 · FY2016 · CA · contact PI
SENIOR LEADERSHIP$417,503
P30 · FY2016 · CA · contact PI
Discovery and Pre-Clinical Translation of Rational Epigenetic-Drug/Targeted-Drug Targeted-Drug Combinations$233,077
P50 · FY2016 · CA · contact PI
Career Development Program$143,106
P50 · FY2016 · CA · contact PI
Developmental Research Program$143,106
P50 · FY2016 · CA · contact PI
Administrative Core$131,912
P50 · FY2016 · CA · contact PI
Regional Oncology Research Center$125,000
P30 · FY2016 · CA · contact PI
Regional Oncology Research Center$114,211
P30 · FY2016 · CA · contact PI
STAFF INVESTIGATORS$103,998
P30 · FY2016 · CA · contact PI
PLANNING AND EVALUATION$67,441
P30 · FY2016 · CA · contact PI
Regional Oncology Research Center$60,000
P30 · FY2016 · CA · contact PI
Regional Oncology Research Center$6,995,267
P30 · FY2015 · CA · contact PI
SPORE in Prostate Cancer$1,793,395
P50 · FY2015 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$498,117
T32 · FY2015 · CA · contact PI
DEVELOPMENTAL FUNDS$457,239
P30 · FY2015 · CA · contact PI
PROGRAM LEADERSHIP$449,436
P30 · FY2015 · CA · contact PI
SENIOR LEADERSHIP$417,503
P30 · FY2015 · CA · contact PI
Discovery and Pre-Clinical Translation of Rational Epigenetic-Drug/Targeted-Drug Targeted-Drug Combinations$225,093
P50 · FY2015 · CA · contact PI
Regional Oncology Research Center$185,800
P30 · FY2015 · CA · contact PI
Developmental Research Program$135,952
P50 · FY2015 · CA · contact PI
Career Development Program$135,952
P50 · FY2015 · CA · contact PI
Administrative Core$129,138
P50 · FY2015 · CA · contact PI
Regional Oncology Research Center$125,000
P30 · FY2015 · CA · contact PI
STAFF INVESTIGATORS$103,998
P30 · FY2015 · CA · contact PI
PLANNING AND EVALUATION$67,441
P30 · FY2015 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$39,754
T32 · FY2015 · CA · contact PI
Regional Oncology Research Center$31,250
P30 · FY2015 · CA · contact PI
Regional Oncology Research Center$6,785,409
P30 · FY2014 · CA · contact PI
SPORE in Prostate Cancer$1,877,328
P50 · FY2014 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$552,512
T32 · FY2014 · CA · contact PI
SENIOR LEADERSHIP$472,620
P30 · FY2014 · CA · contact PI
DEVELOPMENTAL FUNDS$438,819
P30 · FY2014 · CA · contact PI
PROGRAM LEADERSHIP$431,334
P30 · FY2014 · CA · contact PI
Regional Oncology Research Center$324,000
P30 · FY2014 · CA · contact PI
Discovery and Pre-Clinical Translation of Rational Epigenetic-Drug/Targeted-Drug Targeted-Drug Combinations$240,607
P50 · FY2014 · CA · contact PI
Career Development Program$143,052
P50 · FY2014 · CA · contact PI
Developmental Research Program$143,052
P50 · FY2014 · CA · contact PI
Administrative Core$136,811
P50 · FY2014 · CA · contact PI
STAFF INVESTIGATORS$99,811
P30 · FY2014 · CA · contact PI
Regional Oncology Research Center$75,000
P30 · FY2014 · CA · contact PI
PLANNING AND EVALUATION$64,722
P30 · FY2014 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$45,674
T32 · FY2014 · CA · contact PI
Regional Oncology Research Center$6,540,575
P30 · FY2013 · CA · contact PI
SPORE In Prostate Cancer$1,233,307
P50 · FY2013 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$601,428
T32 · FY2013 · CA · contact PI
DEVELOPMENTAL FUNDS$427,516
P30 · FY2013 · CA · contact PI
PROGRAM LEADERSHIP$420,228
P30 · FY2013 · CA · contact PI
SENIOR LEADERSHIP$390,368
P30 · FY2013 · CA · contact PI
STAFF INVESTIGATORS$97,240
P30 · FY2013 · CA · contact PI
PLANNING AND EVALUATION$63,056
P30 · FY2013 · CA · contact PI
Regional Oncology Research Center$50,000
P30 · FY2013 · CA · contact PI
SENIOR LEADERSHIP$50,000
P30 · FY2013 · CA · contact PI
Regional Oncology Research Center$43,750
P30 · FY2013 · CA · contact PI
SENIOR LEADERSHIP$43,750
P30 · FY2013 · CA · contact PI
Screen for Small Molecule Antagonists of MBD2$39,285
R03 · FY2013 · MH · contact PI
Regional Oncology Research Center$6,995,267
P30 · FY2012 · CA · contact PI
SPORE In Prostate Cancer$1,957,034
P50 · FY2012 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$467,852
T32 · FY2012 · CA · contact PI
DEVELOPMENTAL FUNDS$457,239
P30 · FY2012 · CA · contact PI
PROGRAM LEADERSHIP$449,437
P30 · FY2012 · CA · contact PI
SENIOR LEADERSHIP$417,501
P30 · FY2012 · CA · contact PI
GSTP1 Promoter Hypermethylation in Human Prostate Cancer$349,564
R01 · FY2012 · CA · contact PI
STAFF INVESTIGATORS$103,997
P30 · FY2012 · CA · contact PI
Regional Oncology Research Center$75,000
P30 · FY2012 · CA · contact PI
PLANNING AND EVALUATION$67,441
P30 · FY2012 · CA · contact PI
Regional Oncology Research Center$50,000
P30 · FY2012 · CA · contact PI
Screen for Small Molecule Antagonists of MBD2$40,500
R03 · FY2012 · MH · contact PI
SPORE In Prostate Cancer$2,185,002
P50 · FY2011 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$513,531
T32 · FY2011 · CA · contact PI
GSTP1 Promoter Hypermethylation in Human Prostate Cancer$349,564
R01 · FY2011 · CA · contact PI
SPORE In Protate Cancer$2,300,000
P50 · FY2010 · CA · contact PI
Howard/Hopkins Cancer Centers Partnership$986,547
U54 · FY2010 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$428,230
T32 · FY2010 · CA · contact PI
GSTP1 Promoter Hypermethylation in Human Prostate Cancer$360,375
R01 · FY2010 · CA · contact PI
SPORE In Protate Cancer$2,300,000
P50 · FY2009 · CA · contact PI
Howard/Hopkins Cancer Centers Partnership$976,090
U54 · FY2009 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$458,089
T32 · FY2009 · CA · contact PI
GSTP1 Promoter Hypermethylation in Human Prostate Cancer$360,375
R01 · FY2009 · CA · contact PI
SPORE In Protate Cancer$2,300,000
P50 · FY2008 · CA · contact PI
Howard/Hopkins Cancer Centers Partnership$1,000,564
U54 · FY2008 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$467,874
T32 · FY2008 · CA · contact PI
SPORE IN PROSTATE CANCER$2,532,522
P50 · FY2007 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$462,965
T32 · FY2007 · CA · contact PI
GSTP1 Promoter Hypermethylation In Human Prostate Cancer$348,813
R01 · FY2007 · CA · contact PI
MBD2 as a Target for Cancer Prevention and Treatment$307,039
R01 · FY2007 · CA · contact PI
SPORE IN PROSTATE CANCER$2,680,997
P50 · FY2006 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$456,641
T32 · FY2006 · CA · contact PI
GSTP1 Promoter Hypermethylation In Human Prostate Cancer$359,231
R01 · FY2006 · CA · contact PI
MBD2 as a Target for Cancer Prevention and Treatment$283,719
R01 · FY2006 · CA · contact PI
SPORE IN PROSTATE CANCER$125,000
P50 · FY2006 · CA · contact PI
SPORE IN PROSTATE CANCER$2,736,840
P50 · FY2005 · CA
GSTP1 Promoter Hypermethylation In Human Prostate Cancer$367,875
R01 · FY2005 · CA
MBD2 as a Target for Cancer Prevention and Treatment$289,510
R01 · FY2005 · CA
AUA/SBUR Res. Conf.-"Inflammation in Prostate Diseases"$11,000
R13 · FY2005 · DK
SPORE IN PROSTATE CANCER$2,416,793
P50 · FY2004 · CA
GSTP1 Promoter Hypermethylation In Human Prostate Cancer$367,875
R01 · FY2004 · CA
SPORE IN PROSTATE CANCER$1,880,124
P50 · FY2003 · CA
Sulforaphane for prostate cancer prevention$0
P50 · FY2003 · CA
GSTPI PROMOTOR HYPERMETHYLATION IN HUMAN PROSTATE CANCER$331,088
R01 · FY2002 · CA
PROSTATIC TOPOISOMERASES AS THERAPEUTIC DRUG TARGETS$131,614
P50 · FY2002 · CA
RATIONAL PROSTATE CANCER PREVENTION USING GST INDUCERS$131,614
P50 · FY2002 · CA
RATIONAL PROSTATE CANCER PREVENTION USING GST INDUCERS$131,614
P50 · FY2002 · CA
PROSTATIC TOPOISOMERASES AS THERAPEUTIC DRUG TARGETS$131,614
P50 · FY2002 · CA
Effects of CAM interventions on oxidative damage in cancer cells$0
P50 · FY2002 · AT
GSTPI PROMOTOR HYPERMETHYLATION IN HUMAN PROSTATE CANCER$331,172
R01 · FY2001 · CA
RATIONAL PROSTATE CANCER PREVENTION USING GST INDUCERS$131,614
P50 · FY2001 · CA
RATIONAL PROSTATE CANCER PREVENTION USING GST INDUCERS$131,614
P50 · FY2001 · CA
PROSTATIC TOPOISOMERASES AS THERAPEUTIC DRUG TARGETS$131,614
P50 · FY2001 · CA
PROSTATIC TOPOISOMERASES AS THERAPEUTIC DRUG TARGETS$131,614
P50 · FY2001 · CA
Effects of CAM interventions on oxidative damage in cancer cells$0
P50 · FY2001 · AT
GSTPI PROMOTER HYPERMETHYLATION IN HUMAN PROSTATE CANCER$332,100
R01 · FY2000 · CA
PROSTATIC TOPOISOMERASES AS THERAPEUTIC DRUG TARGETS$131,614
P50 · FY2000 · CA
RATIONAL PROSTATE CANCER PREVENTION USING GST INDUCERS$131,614
P50 · FY2000 · CA
RATIONAL PROSTATE CANCER PREVENTION USING GST INDUCERS$131,614
P50 · FY2000 · CA
PROSTATIC TOPOISOMERASES AS THERAPEUTIC DRUG TARGETS$131,614
P50 · FY2000 · CA
Effects of CAM interventions on oxidative damage in cancer cells$0
P50 · FY2000 · AT